Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Autolus Therapeutics plc AUTL

Healthcare Biotechnology
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy... see more

Recent & Breaking News (NDAQ:AUTL)

Autolus Therapeutics to Host R&D Day on March 26, 2019

GlobeNewswire March 7, 2019

Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

GlobeNewswire March 4, 2019

Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019

GlobeNewswire March 4, 2019

Vineti announces strategic partnership with Autolus Therapeutics to support delivery of novel T cell therapies

GlobeNewswire February 25, 2019

Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018

PR Newswire February 25, 2019

Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019

PR Newswire February 21, 2019

Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial

PR Newswire Europe Non Regulatory February 19, 2019

Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris

PR Newswire February 19, 2019

Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters

PR Newswire January 14, 2019

Autolus Therapeutics to Join NASDAQ Biotechnology Index

PR Newswire December 20, 2018

Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes

PR Newswire Europe Non Regulatory December 3, 2018

Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH

PR Newswire Europe Non Regulatory December 3, 2018

Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting

PR Newswire December 2, 2018

Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

PR Newswire December 1, 2018

Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

PR Newswire November 23, 2018

Autolus Therapeutics to Present New Data at the ASH Annual Meeting

PR Newswire Europe Non Regulatory November 2, 2018

Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting

PR Newswire November 1, 2018

Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference

PR Newswire October 30, 2018

Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality

PR Newswire October 17, 2018

Autolus to Present at Upcoming Investor Conferences

PR Newswire August 30, 2018